Clinical Trials Browser

Carcinoma, Non-Small-Cell Lung × brigatinib × 1 year × Clear all

NCT05721950 2026-02-18

Brilliant

Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04223596 2026-02-04

CUBIK

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT05200481 2025-11-17

MP-ALK

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT03707938 2025-11-03

Local Consolidative Therapy and Brigatinib in Treating Patients With Stage IV or Recurrent Non-small Cell Lung Cancer

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT04227028 2025-09-16

Brigatinib and Bevacizumab for the Treatment of ALK-Rearranged Locally Advanced, Metastatic, or Recurrent NSCLC

Phase 1 Active not recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT06522360 2025-04-24

Brigatinib Plus Chemotherapy or Local Consolidation Therapy in ALK Positive Advanced Non-small Cell Lung Cancer (BrightStar-2)

Phase 2 Withdrawn

Carcinoma, Non-Small-Cell Lung

NCT05834348 2025-03-30

DELINOR

5,279 enrolled 10 charts

Carcinoma, Non-Small-Cell Lung